Meeting
2023 ASCO Annual Meeting
Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.
Authors
Kunal Desai
University of Chicago Medical Center, Chicago, IL
Kunal Desai , Anthony V. Serritella , Walter Michael Stadler , Peter H. O'Donnell , Randy F. Sweis , Russell Zelig Szmulewitz
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Prostate, Testicular, and Penile
Track
Genitourinary Cancer—Prostate, Testicular, and Penile
Sub Track
Prostate Cancer– Advanced/Castrate-Resistant
Clinical Trial Registration Number
NCT03674814
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 5062)
DOI
10.1200/JCO.2023.41.16_suppl.5062
Abstract #
5062
Poster Bd #
156
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
CYCLONE 2: A phase II, randomized, placebo-controlled study of abiraterone acetate plus prednisone with or without abemaciclib in patients with metastatic castration-resistant prostate cancer.
First Author: Matthew Raymond Smith
Poster
2013 Genitourinary Cancers Symposium
Enzalutamide in combination with docetaxel in men with prostate cancer (PC): Preliminary results from a phase I study.
First Author: Mark T. Fleming
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
First Author: Karim Fizazi
Poster
2020 ASCO Virtual Scientific Program
Phase I study of AMG 509, a STEAP1 x CD3 T cell-recruiting XmAb 2+1 immune therapy, in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: W. Kevin Kelly